Oprah Winfrey's Stunning Look at 72: Her Paris Fashion Week Moment and GLP-1 Weight Loss Journey
WeightWatchers stock fell 25% after Oprah left the board—now she's the face of the drugs that could threaten its business model

Oprah Winfrey doesn't do anything small. Not her talk show. Not her book club. And certainly not her weight loss.
The 72-year-old billionaire sat front row at both the Stella McCartney and Chloé shows on 4 and 5 March during Paris Fashion Week, her slimmed-down frame impossible to ignore. She's lost more than 50 pounds over the past two and a half years using GLP-1 medications, the same class of drugs that includes Ozempic and Wegovy. The photos went viral within hours.
But here's what makes her Paris appearance more than just another celebrity fashion moment: Winfrey walked away from WeightWatchers in 2024. And the company she once championed as a 'lifestyle' approach to weight management is now fighting for survival.
The Exit That Crashed a Stock
Winfrey joined the WeightWatchers board in 2015. She invested $43.2 million (£32.3 million) and let the company use her name and face in its marketing. The stock soared.
Then came February 2024. Winfrey announced she wouldn't stand for re-election to the board. According to ABC, WeightWatchers shares dropped 25% in premarket trading the next day, hitting their lowest point since 2001.
She also donated her entire stake in the company to the National Museum of African American History and Culture. WeightWatchers said the move was partly 'to eliminate any perceived conflict of interest around her taking weight loss medications.'
The company built its brand on counting points and changing habits. Now, its most famous advocate is a walking advertisement for the pharmaceutical industry.
$990 Heels, $1,500-a-Month Drugs
According to reports, Winfrey wore the designer's Elsa pumps in black at the Stella McCartney show, held at the Le Grand Manege Jean Caucanas equestrian centre. Price tag: $990 (£741), WWD reported. Her best friend, Gayle King, seated beside her, wore the same style in brown crocodile-effect.
The next day at Chloé, they matched again—in snake-effect Cleia pumps.
Celebrities wear expensive shoes. That's no news. But it's worth noting who can actually afford the drugs that brought Winfrey here. GLP-1 medications cost between $1,000 and $1,500 (£748 to £1,122) monthly without insurance in the US. In the UK, Wegovy is technically available on the NHS, but strict eligibility rules and shortages push most patients toward private prescriptions.
The math is simple: if you can't afford the treatment, you can't get the results.
What Oprah Says About Her Weight Now
Winfrey has been open about her shift in thinking. In her upcoming book, 'Enough: Your Health, Your Weight and What It's Like to Be Free,' written with obesity specialist Dr. Ania M. Jastreboff, she explains her changed perspective.
'I came to understand that overeating doesn't cause obesity. Obesity causes overeating,' she told People magazine. 'And that's the most mind-blowing, freeing thing I've experienced as an adult.'
She's also said this isn't temporary. 'It's going to be a lifetime thing,' Winfrey shared, comparing GLP-1 drugs to high blood pressure medication. She reached her goal weight of 155 pounds and now exercises two hours a day, six days a week. She's stopped drinking alcohol entirely.
The Question Nobody Wants to Ask
At 72, Winfrey looks healthy. She sounds at peace. And she's using her platform to push back against the shame that surrounded her weight for decades.
But there's a tension here that's hard to ignore. For 25 years, Winfrey built an empire partly on the promise that willpower and lifestyle changes could work. She admits she was wrong. The science, she says, shows obesity is a disease that often requires medical treatment.
That's a fair point backed by research. Still, the people watching from home don't all have her resources. They can't afford the monthly prescriptions, the personal trainers, or the front-row seats in Paris.
Winfrey's transformation is real. So is the gap between what she can access and what millions of others can't.
© Copyright IBTimes 2025. All rights reserved.




















